159 related articles for article (PubMed ID: 12490739)
1. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.
Kruijtzer CM; Beijnen JH; Schellens JH
Oncologist; 2002; 7(6):516-30. PubMed ID: 12490739
[TBL] [Abstract][Full Text] [Related]
2. Modulation of oral bioavailability of anticancer drugs: from mouse to man.
Schellens JH; Malingré MM; Kruijtzer CM; Bardelmeijer HA; van Tellingen O; Schinkel AH; Beijnen JH
Eur J Pharm Sci; 2000 Dec; 12(2):103-10. PubMed ID: 11102737
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
4. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
5. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
[TBL] [Abstract][Full Text] [Related]
6. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
7. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
Kuppens IE; Breedveld P; Beijnen JH; Schellens JH
Cancer Invest; 2005; 23(5):443-64. PubMed ID: 16193644
[TBL] [Abstract][Full Text] [Related]
8. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Bardelmeijer HA; van Tellingen O; Schellens JH; Beijnen JH
Invest New Drugs; 2000 Aug; 18(3):231-41. PubMed ID: 10958591
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
10. The biological and clinical role of drug transporters at the intestinal barrier.
Oostendorp RL; Beijnen JH; Schellens JH
Cancer Treat Rev; 2009 Apr; 35(2):137-47. PubMed ID: 18986769
[TBL] [Abstract][Full Text] [Related]
11. Boosting bioavailability of topotecan: what do we gain?
Hudes G
J Clin Oncol; 2002 Jul; 20(13):2918-9. PubMed ID: 12089219
[No Abstract] [Full Text] [Related]
12. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Breedveld P; Beijnen JH; Schellens JH
Trends Pharmacol Sci; 2006 Jan; 27(1):17-24. PubMed ID: 16337012
[TBL] [Abstract][Full Text] [Related]
13. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
14. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
15. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
16. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum.
Gravel S; Panzini B; Belanger F; Turgeon J; Michaud V
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269743
[TBL] [Abstract][Full Text] [Related]
18. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
Rudek MA; Zhao M; Smith NF; Robey RW; He P; Hallur G; Khan S; Hidalgo M; Jimeno A; Colevas AD; Messersmith WA; Wolff AC; Baker SD
Clin Cancer Res; 2005 Dec; 11(23):8503-11. PubMed ID: 16322314
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.
Kwak JO; Lee SH; Lee GS; Kim MS; Ahn YG; Lee JH; Kim SW; Kim KH; Lee MG
Eur J Pharmacol; 2010 Feb; 627(1-3):92-8. PubMed ID: 19903471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
